Categories AlphaGraphs, Earnings, LATEST, Retail

Constellation Brands brews earnings beat in Q2

Constellation Brands Inc. (STZ) topped market estimates on sales and earnings for the second quarter of 2019. Shares were up over 3% during premarket hours on Thursday.

The New York-based brewer reported net sales of $2.3 billion, up 10% compared to the same period last year. Net income attributable to Constellation Brands increased 136% to $1.14 billion or $5.87 per share from the prior-year period. Comparable EPS grew 16% to $2.87.

Constellation Brands second quarter 2019 earnings
Constellation Brands Q2 2019 Earnings Infographic

The company posted sales increases in both its Beer and Wine and Spirits divisions. In the beer division, the Modelo and Corona brands drove strong portfolio performance and market share gains with depletion growth of 10%. In the wine and spirits division, net sales benefited from strong shipment volume growth.

For the full year of 2019, the company expects reported EPS to come in the range of $14.10 to $14.25 and comparable EPS to come in the range of $9.60 to $9.75.

The beer business expects net sales and operating income growth of 9% to 11% while the wine and spirits business expects net sales and operating income growth of 2% to 4% for 2019.

On October 3, Constellation declared quarterly cash dividends of $0.74 per share of Class A common stock and $0.67 per share of Class B common stock, payable on November 20 to shareholders of record on November 6.

In August, the company had announced its plan to invest $4 billion in Canopy Growth Corporation, thereby increasing its stake to 38% in the medical marijuana company. The transaction is expected to close by October-end.

Constellation Brands looks to cannabis for a high, ups stake in Canopy

Also Read:  Acuity Brands Q2 profit dips 32% but beats estimates

Most Popular

BlackBerry (BB) likely to report weak Q4 earnings on March 31

BlackBerry Limited (NYSE: BB) is slated to report its fourth-quarter 2020 earnings results on Tuesday, March 31, after the market closes. The top line will be benefited by BlackBerry Cylance

Companies that are working on the coronavirus vaccine

The coronavirus pandemic continues to plague the world with over 500,000 cases reported globally and over 82,000 cases in the US alone. As the world grapples with the outbreak, several

Altimmune (ALT) reports FY19 results; announces vaccine candidate for COVID-19

Altimmune Inc. (NASDAQ: ALT) reported its earnings results for fiscal-year 2019. Revenues totaled $5.8 million compared to $10.3 million last year. The drop in revenues was caused by lower billings

Tags